We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Counting sheep

12 February 2004 By Robert Cyran

The world s secondlargest drugs company expects stagnant profits this year as generic drug competition eats into sales. But 2004 will be a lowwater mark. And Glaxo’s burgeoning pipeline makes the stock look dead cheap.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)